

# William Y K Hwang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7249464/publications.pdf>

Version: 2024-02-01

165  
papers

4,999  
citations

147566

31  
h-index

106150

65  
g-index

167  
all docs

167  
docs citations

167  
times ranked

9838  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	1.6	766
2	Immunogenicity of engineered antibodies. Methods, 2005, 36, 3-10.	1.9	519
3	Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. Immunity, 2018, 48, 364-379.e8.	6.6	450
4	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). European Journal of Immunology, 2021, 51, 2708-3145.	1.6	198
5	A Meta-Analysis of Unrelated Donor Umbilical Cord Blood Transplantation versus Unrelated Donor Bone Marrow Transplantation in Adult and Pediatric Patients. Biology of Blood and Marrow Transplantation, 2007, 13, 444-453.	2.0	156
6	Combinatorial Single-Cell Analyses of Granulocyte-Monocyte Progenitor Heterogeneity Reveals an Early Uni-potent Neutrophil Progenitor. Immunity, 2020, 53, 303-318.e5.	6.6	153
7	The CD4 <sup>+</sup> CD8 <sup>+</sup> MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8 <sup>+</sup> MAIT cell pool. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11513-E11522.	3.3	147
8	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infectious Diseases, The, 2019, 19, 988-1000.	4.6	136
9	Electrospun nanofiber scaffolds for rapid and rich capture of bone marrow-derived hematopoietic stem cells. Biomaterials, 2008, 29, 2096-2103.	5.7	131
10	Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore. Cell, 2019, 179, 736-749.e15.	13.5	126
11	Use of Fluid-Ventilated, Gas-Permeable Scleral Lens for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2007, 13, 1016-1021.	2.0	115
12	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. Journal of Clinical Oncology, 2019, 37, 367-374.	0.8	110
13	Understanding the Psychological Impact of COVID-19 Pandemic on Patients With Cancer, Their Caregivers, and Health Care Workers in Singapore. JCO Global Oncology, 2020, 6, 1494-1509.	0.8	95
14	Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. Gastroenterology, 2019, 156, 1862-1876.e9.	0.6	92
15	Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods, 2005, 36, 35-42.	1.9	82
16	Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica, 2011, 96, 942-947.	1.7	75
17	The N3XT Approach to Energy-Efficient Abundant-Data Computing. Proceedings of the IEEE, 2019, 107, 19-48.	16.4	71
18	The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplantation, 2012, 47, 957-966.	1.3	68

#	ARTICLE	IF	CITATIONS
19	Mesenchymal Stem Cells Secreting Angiopoietin-Like-5 Support Efficient Expansion of Human Hematopoietic Stem Cells Without Compromising Their Repopulating Potential. <i>Stem Cells and Development</i> , 2011, 20, 1371-1381.	1.1	61
20	Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. <i>Blood</i> , 2021, 138, 1429-1440.	0.6	54
21	Expansion of Human Cord Blood Hematopoietic Stem Cells for Transplantation. <i>Cell Stem Cell</i> , 2010, 7, 427-428.	5.2	52
22	A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. <i>Bone Marrow Transplantation</i> , 2015, 50, 334-340.	1.3	50
23	Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e326-e333.	2.2	50
24	Hyperdimensional Computing Exploiting Carbon Nanotube FETs, Resistive RAM, and Their Monolithic 3D Integration. <i>IEEE Journal of Solid-State Circuits</i> , 2018, 53, 3183-3196.	3.5	49
25	Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy. <i>Leukemia</i> , 2019, 33, 1487-1500.	3.3	48
26	Expansion and Homing of Umbilical Cord Blood Hematopoietic Stem and Progenitor Cells for Clinical Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1008-1019.	2.0	46
27	Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. <i>Leukemia</i> , 2020, 34, 3413-3419.	3.3	42
28	Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2005, 159, 129-136.	1.0	40
29	A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. <i>Cytotherapy</i> , 2012, 14, 851-859.	0.3	40
30	Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group. <i>Bone Marrow Transplantation</i> , 2010, 45, 1682-1691.	1.3	39
31	Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. <i>Annals of Oncology</i> , 2012, 23, 421-426.	0.6	37
32	A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 51-56.	1.3	30
33	Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 167-172.	0.6	27
34	Nonhuman primate allogeneic hematopoietic stem cell transplantation by intraosseus vs intravenous injection: Engraftment, donor cell distribution, and mechanistic basis. <i>Experimental Hematology</i> , 2008, 36, 1556-1566.	0.2	25
35	Ex Vivo Expansion of CD34+CD90+CD49f+ Hematopoietic Stem and Progenitor Cells from Non-Enriched Umbilical Cord Blood with Azole Compounds. <i>Stem Cells Translational Medicine</i> , 2018, 7, 376-393.	1.6	23
36	Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	23

#	ARTICLE	IF	CITATIONS
37	Protective role of functionalized single walled carbon nanotubes enhance ex vivo expansion of hematopoietic stem and progenitor cells in human umbilical cord blood. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 1304-1316.	1.7	22
38	Mesenchymal stromal cell supported umbilical cord blood ex vivo expansion enhances regulatory T cells and reduces graft versus host disease. <i>Cytotherapy</i> , 2013, 15, 610-619.	0.3	22
39	Distinct Responses of Stem Cells to Telomere Uncapping—A Potential Strategy to Improve the Safety of Cell Therapy. <i>Stem Cells</i> , 2016, 34, 2471-2484.	1.4	22
40	Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia Following Nonmyeloablative Conditioning Using 200-cGy Total Body Irradiation and Fludarabine. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 887-890.	2.0	21
41	Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective. <i>Journal of Medical Economics</i> , 2020, 23, 1321-1329.	1.0	20
42	Low-dose insulin-like growth factor binding proteins 1 and 2 and angiopoietin-like protein 3 coordinately stimulate ex vivo expansion of human umbilical cord blood hematopoietic stem cells as assayed in NOD/SCID gamma null mice. <i>Stem Cell Research and Therapy</i> , 2014, 5, 71.	2.4	19
43	Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group. <i>Bone Marrow Transplantation</i> , 2016, 51, 933-937.	1.3	18
44	Respiratory virus infection after allogeneic hematopoietic stem cell transplant in a tropical center: Predictive value of the immunodeficiency scoring index. <i>Transplant Infectious Disease</i> , 2017, 19, e12693.	0.7	18
45	Successful treatment of primary granulocytic sarcoma by non-myeloablative stem cell transplant. <i>Leukemia and Lymphoma</i> , 2006, 47, 159-162.	0.6	17
46	Pre-transplant achievement of negativity in minimal residual disease and French-American-British L1 morphology predict superior outcome after allogeneic transplant for Philadelphia chromosome positive acute lymphoblastic leukemia: an analysis of Southeast Asian patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 1362-1369.	0.6	17
47	An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era. <i>American Journal of Hematology</i> , 2010, 85, 752-756.	2.0	16
48	Comparing peripheral blood stem cell collection using the COBE Spectra, Haemonetics MCS+, and Baxter Amicus. <i>Transfusion and Apheresis Science</i> , 2012, 47, 345-350.	0.5	16
49	Effect of Cord Blood Processing on Transplantation Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 688-695.	2.0	16
50	Fanconi's Anemia in Adulthood: Chemoradiation-Induced Bone Marrow Failure and a Novel FANCA Mutation Identified by Targeted Deep Sequencing. <i>Journal of Clinical Oncology</i> , 2011, 29, e591-e594.	0.8	15
51	HLA Haplotypes in Singapore: A Study of Mothers and Their Cord Blood Units. <i>Human Immunology</i> , 2007, 68, 430-438.	1.2	14
52	Intercellular cytosolic transfer correlates with mesenchymal stromal cell rescue of umbilical cord blood cell viability during ex vivo expansion. <i>Cytotherapy</i> , 2012, 14, 1064-1079.	0.3	14
53	Study of gene expression profile during cord blood-associated megakaryopoiesis. <i>European Journal of Haematology</i> , 2008, 81, 196-208.	1.1	13
54	Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients. <i>Bone Marrow Transplantation</i> , 2010, 45, 1031-1037.	1.3	13

#	ARTICLE	IF	CITATIONS
55	Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1382-1386.	0.6	13
56	Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia. <i>Haematologia</i> , 2001, 31, 73-80.	0.2	12
57	Unrelated peripheral blood and cord blood hematopoietic stem cell transplants for thalassemia major. <i>American Journal of Hematology</i> , 2004, 75, 209-212.	2.0	12
58	BK-virus prophylaxis: still no answer. <i>Bone Marrow Transplantation</i> , 2013, 48, 1362-1363.	1.3	12
59	The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2336-2341.	0.6	12
60	Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1971-1980.	2.0	12
61	A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL). <i>Blood</i> , 2014, 124, 503-503.	0.6	12
62	Biological characteristics of megakaryocytes: Specific lineage commitment and associated disorders. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 1821-1826.	1.2	11
63	Cotransplantation of Ex Vivo Expanded and Unexpanded Cord Blood Units in Immunodeficient Mice Using Insulin Growth Factor Binding Protein-2 Augmented Mesenchymal Cell Cocultures. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 674-682.	2.0	11
64	Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 1506-1509.	1.3	11
65	Minimizing transmission of COVID-19 while delivering optimal cancer care in a National Cancer Centre. <i>Journal of Cancer Policy</i> , 2020, 25, 100241.	0.6	11
66	Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis. <i>Bone Marrow Transplantation</i> , 2003, 31, 305-308.	1.3	10
67	Successful Treatment of Idiopathic Hypereosinophilic Syndrome with Imatinib Mesylate: A Case Report. <i>International Journal of Hematology</i> , 2004, 80, 75-77.	0.7	10
68	Impact of Postgrafting Immunosuppressive Regimens on Nonrelapse Mortality and Survival after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant Using the Fludarabine and Low-Dose Total-Body Irradiation 200-cGy. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 790-805.	2.0	10
69	Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells. <i>Journal of Hematology and Oncology</i> , 2008, 1, 19.	6.9	10
70	The Impact of COVID-19 on Cancer Care in the Post Pandemic World: Five Major Lessons Learnt from Challenges and Countermeasures of Major Asian Cancer Centres. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 681-690.	0.5	10
71	Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. <i>Oncotarget</i> , 2017, 8, 25455-25468.	0.8	10
72	Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling?evaluation of risks and benefits. <i>Annals of Hematology</i> , 2004, 83, 286-294.	0.8	9

#	ARTICLE	IF	CITATIONS
73	Identification of nine new HLA class I alleles in volunteers from the Singapore stem cell donor registries. <i>Tissue Antigens</i> , 2006, 68, 518-520.	1.0	9
74	Successful Autologous Hematopoietic Stem Cell Transplantations for Severe Multiple Sclerosis with Fludarabine and Cyclophosphamide Conditioning. <i>International Journal of Hematology</i> , 2006, 83, 368-369.	0.7	9
75	Mitochondrial superoxide reduction and cytokine secretion skewing by carbon nanotube scaffolds enhance ex vivo expansion of human cord blood hematopoietic progenitors. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1643-1656.	1.7	9
76	What We Learned From Plasma BK-Virus Monitoring in Allogeneic Hematopoietic Transplant Recipients. <i>Transplantation</i> , 2016, 100, e17-e18.	0.5	9
77	Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 117-121.	0.2	9
78	Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective. <i>Journal of Medical Economics</i> , 2021, 24, 637-653.	1.0	9
79	An Asian Body to Tackle Cancers in Asia – The Asian National Cancer Centers Alliance. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 1207-1212.	0.5	9
80	Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2010, 45, 1625-1630.	1.3	8
81	Inadvertent completely HLA-mismatched allogeneic unrelated bone marrow transplant: lessons learned. <i>Bone Marrow Transplantation</i> , 2016, 51, 1016-1018.	1.3	8
82	Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 222-231.	0.7	8
83	Severe acute graft-versus-host disease occurring after syngeneic BMT for AML in a patient not given prior cyclosporin A therapy. <i>Bone Marrow Transplantation</i> , 2000, 25, 205-207.	1.3	7
84	Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 72-79.	0.6	7
85	Acarbose is an effective treatment for severe hypertriglyceridemia secondary to asparaginase and dexamethasone. <i>Leukemia and Lymphoma</i> , 2012, 53, 1245-1246.	0.6	7
86	Safety of Living Donation of Hematopoietic Stem Cells. <i>Transplantation</i> , 2016, 100, 1329-1331.	0.5	7
87	Recurrent trichosporonosis with central nervous system involvement in an allogeneic hematopoietic stem cell transplant recipient. <i>Transplant Infectious Disease</i> , 2016, 18, 768-772.	0.7	7
88	Coming Up N3XT, After 2D Scaling of Si CMOS. , 2018, , .		7
89	Stem cell transplantation programme at Singapore General Hospital. <i>Bone Marrow Transplantation</i> , 2008, 42, S121-S124.	1.3	6
90	3D nanosystems enable embedded abundant-data computing. , 2017, , .		6

#	ARTICLE	IF	CITATIONS
91	Donorâ€™type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant. <i>Transfusion</i> , 2019, 59, 335-339.	0.8	6
92	Cancer Versus COVID-19: A Coordinated Disease Outbreak Response System (DORS) to Combat COVID-19 at the National Cancer Centre Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2020, 49, 807-809.	0.2	6
93	Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective. <i>ClinicoEconomics and Outcomes Research</i> , 2022, Volume 14, 333-355.	0.7	6
94	Decoupling of normal CD40/interleukin-4 immunoglobulin heavy chain switch signal leads to genomic instability in SGH-MM5 and RPMI 8226 multiple myeloma cell lines. <i>Leukemia</i> , 2006, 20, 715-723.	3.3	5
95	Characterization of new HLAâ€™B and â€™DRB1 alleles from Singapore. <i>Tissue Antigens</i> , 2009, 73, 75-76.	1.0	5
96	A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of <i>&lt;i&gt;HLA-DRB1*12:02&lt;/i&gt;</i> . <i>Pharmacogenomics</i> , 2016, 17, 1235-1243.	0.6	5
97	Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity. <i>Blood</i> , 2018, 132, 2676-2676.	0.6	5
98	Novel HLA class I and II alleles identified during routine registry typing in 2010. <i>Tissue Antigens</i> , 2011, 78, 263-266.	1.0	4
99	Longâ€™term renal outcome after allogeneic hemopoietic stem cell transplant: A comprehensive analysis of risk factors in an Asian patient population. <i>Clinical Transplantation</i> , 2017, 31, e12920.	0.8	4
100	Durable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphoma. <i>Annals of Hematology</i> , 2017, 96, 1959-1960.	0.8	4
101	An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication. <i>Bone Marrow Transplantation</i> , 2017, 52, 363-371.	1.3	4
102	Early Outcomes of a National Cancer Center's Strategy Against COVID-19 Executed Through a Disease Outbreak Response Taskforce. <i>JCO Oncology Practice</i> , 2021, 17, e343-e354.	1.4	4
103	Mixed Phenotype Acute Leukemia with Low Hypodiploidy in a Pediatric Patient. <i>Journal of Pediatric Oncology</i> , 2015, 3, 24-28.	0.1	4
104	Myelodysplastic syndrome with transformation to AML-M7 in a 46,XX male patient. <i>Cancer Genetics and Cytogenetics</i> , 2002, 136, 153-154.	1.0	3
105	Use of ultraviolet-light irradiated multiple myeloma cells as immunogens to generate tumor-specific cytolytic T lymphocytes. <i>Journal of Immune Based Therapies and Vaccines</i> , 2008, 6, 2.	2.4	3
106	Characterization of hemopoietic engraftment kinetics and development of secondary cytopenia in AML post auto-SCT and its correlation with survival outcome. <i>Bone Marrow Transplantation</i> , 2009, 44, 175-183.	1.3	3
107	WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients. <i>Annals of Hematology</i> , 2015, 94, 761-769.	0.8	3
108	Proptosis in a Patient With Known Graft Versus Host Disease. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2019, 35, e142-e145.	0.4	3

#	ARTICLE	IF	CITATIONS
109	Facilitating timely cancer care in a surgical oncology subspecialty unit during the pandemic and recovery phase of the COVID era. <i>Asian Journal of Surgery</i> , 2020, 43, 965-966.	0.2	3
110	Combined interstitial and surface high-dose-rate brachytherapy treatment of squamous cell carcinoma of the hand. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 48-52.	0.4	3
111	Use of Immunoglobulin Infusions in the Management of Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma. <i>Blood</i> , 2006, 108, 5097-5097.	0.6	3
112	Allogeneic haematopoietic stem cell transplantation without a matched sibling donor: current options and future potential. <i>Annals of the Academy of Medicine, Singapore</i> , 2009, 38, 340-6.	0.2	3
113	Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Advances in Hematology</i> , 2009, 2009, 1-4.	0.6	2
114	Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 181-189.	1.3	2
115	Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation. <i>BMC Hematology</i> , 2015, 15, 8.	2.6	2
116	World Cancer Day 2021: Remembering the ongoing cancer pandemic. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 107-108.	0.2	2
117	Editorial: Recent Developments in Haploidentical Hematopoietic Cell Transplantation: Therapy and Complications. <i>Frontiers in Immunology</i> , 2021, 12, 746221.	2.2	2
118	Cytokine Induced Killer Cells Are Feasible and Safe for Both Autologous and Allogeneic Applications in Patients with Haematological Malignancies. <i>Blood</i> , 2008, 112, 2917-2917.	0.6	2
119	Treatment of blastic plasmacytoid dendritic cell neoplasms with cord blood transplants. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 569-70.	0.3	2
120	Studies of Wilms's Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore. <i>Biomarker Insights</i> , 2007, 2, 117727190700200.	1.0	1
121	Cord blood unit factors influencing transplant outcomes from the Asian multiethnic Singapore Cord Blood Bank. <i>Bone Marrow Transplantation</i> , 2015, 50, 1256-1258.	1.3	1
122	Preparing for the Next Pandemic: An Asian National Cancer Centers Alliance (ANCCA) Initiative. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2945-2950.	0.5	1
123	Low Dose Dexamethasone and Thalidomide with Higher Frequency Zoledronic Acid (dtZ) for Multiple Myeloma. <i>Blood</i> , 2004, 104, 4915-4915.	0.6	1
124	Outpatient-Based Therapy with Oral Fludarabine and Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2006, 108, 4992-4992.	0.6	1
125	Small Molecule Based Ex Vivo Expansion of CD34+CD90+CD49f+ Hematopoietic Stem & Progenitor Cells from Non-Enriched Umbilical Cord Blood Mononucleated Cells. <i>Blood</i> , 2016, 128, 2321-2321.	0.6	1
126	High Dose Cytarabine Is Superior to Intermediate Dose Cytarabine As Post-Remission Therapy for Younger Patients with Favorable Risk Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 4032-4032.	0.6	1

#	ARTICLE	IF	CITATIONS
127	High Response and Complete Remission Rates in Relapsed/Refractory Multiple Myeloma Treated with Bortezomib, Thalidomide, Dexamethasone and Zoledronic Acid (VTD-Z) Combination Therapy.. Blood, 2005, 106, 5127-5127.	0.6	1
128	Banking of Cord Blood. , 2010, , 291-320.		1
129	Mefloquine Effectively Targets Blast Phase Chronic Myeloid Leukemia through Inducing Oxidative Stress and Lysosomal Disruption. Blood, 2016, 128, 5426-5426.	0.6	1
130	Blood stem cell donation: a model for worldwide cooperation in transplantation. Annals of the Academy of Medicine, Singapore, 2014, 43, 294-5.	0.2	1
131	World Cancer Day 2021: Remembering the ongoing cancer pandemic. Annals of the Academy of Medicine, Singapore, 2021, 50, 107-108.	0.2	1
132	High-dose chemotherapy and autologous stem cell rescue for acute myeloid leukemia remains a safe, effective, and valid option. Transplantation Proceedings, 2000, 32, 2464-2466.	0.3	0
133	124: Mesenchymal Stem Cells Support ex vivo Umbilical Cord Blood Expansion by a Contact-Dependent Anti-Apoptotic Effect. Biology of Blood and Marrow Transplantation, 2008, 14, 47-48.	2.0	0
134	The Effect of Donor Cytomegalovirus (CMV) Serologic Status on Outcome and Survival in Patients Undergoing Allogenic Stem Cell Transplantation in the Era of CMV-Preemptive Therapy. Biology of Blood and Marrow Transplantation, 2011, 17, S280-S281.	2.0	0
135	Retrospective Analysis of Effectiveness of Venocclusive Prophylaxis Guidelines Implemented for Patients Receiving Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, S191.	2.0	0
136	Treatment of advanced stage <sc>H</sc>odgkin lymphoma â€“ it's all about riskâ€“benefit. British Journal of Haematology, 2012, 159, 113-115.	1.2	0
137	Evaluation of Revised Vaccination Guideline for Hematopoietic Cell Transplant Patients in Singapore General Hospital. Biology of Blood and Marrow Transplantation, 2014, 20, S292-S293.	2.0	0
138	Race Influences the Response to Conventional Induction Chemotherapy in Asian Patients with Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, S187-S188.	2.0	0
139	Transplant Outcomes and Early Relapse after Novel and Non-Novel Agent Induction: An Analysis By Singapore Myeloma Working Group. Biology of Blood and Marrow Transplantation, 2016, 22, S221.	2.0	0
140	Personalized T cell therapy against HBV-related hepatocellularcarcinoma. Journal of Hepatology, 2018, 68, S12-S13.	1.8	0
141	PS-141-CytoF-based immune monitoring of HBV-HCC patients receiving autologous anti-tumour T-cell therapy. Journal of Hepatology, 2019, 70, e89-e90.	1.8	0
142	Hematopoietic Stem Cell Expansion. Annals of Oncology, 2019, 30, vi74.	0.6	0
143	Harnessing MSC Osteoprogenitor Subpopulations to Augment Hematopoietic Transplantations. Biology of Blood and Marrow Transplantation, 2019, 25, S166.	2.0	0
144	So, you want to be a doctor?. Internal Medicine Journal, 2019, 49, 407-408.	0.5	0

#	ARTICLE	IF	CITATIONS
145	Mobilization kinetics of peripheral blood stem cells with rescue plerixafor " real-world experience from a single center. <i>Leukemia and Lymphoma</i> , 2020, 61, 1740-1743.	0.6	0
146	CD40 Ligand Stimulation of Multiple Myeloma Cells Results in Upregulation of Surface Expressed Heat Shock Proteins and Increased Antigenicity.. <i>Blood</i> , 2004, 104, 3351-3351.	0.6	0
147	Decoupling of Normal CD40 / Interleukin-4 Immunoglobulin Heavy Chain Switch Signal Leads to Genomic Instability in RPMI 8226 and SGH-MM5 Multiple Myeloma Cell Lines.. <i>Blood</i> , 2004, 104, 1424-1424.	0.6	0
148	Nutritional Anemias. , 2004, , 559-570.		0
149	Campath-1H-Regulated Ex Vivo Expansion of Cord Blood: Selection of Stem Cells, Depletion of Lymphocytes and Preferential Expansion of Myeloid, Megakaryocytic and Erythroid Precursors.. <i>Blood</i> , 2006, 108, 3644-3644.	0.6	0
150	The Haemophagocytic Syndrome Re-Visited: A Unique Asian Perspective.. <i>Blood</i> , 2006, 108, 3840-3840.	0.6	0
151	Comparison of Donor Cell Homing Efficiency between Intraosseus and Intravenous Injection in Primate Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 3206-3206.	0.6	0
152	Factors Influencing Responsiveness to Bortezomib in Patients with Multiple Myeloma Suggest a Possible Role for Host Immunocompetency.. <i>Blood</i> , 2006, 108, 5100-5100.	0.6	0
153	Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response. <i>Blood</i> , 2010, 116, 3056-3056.	0.6	0
154	Functionalized Carbon Nanotubes Increase the Viability of Post-Thaw Cord Blood Cells and Enhance the Overall Hematopoietic Progenitor Cell Expansion in Ex Vivo Culture. <i>Blood</i> , 2011, 118, 1327-1327.	0.6	0
155	Effectiveness of Ursodeoxycholic Acid As Prophylactic Agent Against Hepatic Sinusoidal Obstruction Syndrome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Treatment of Hematological Malignancies. <i>Blood</i> , 2012, 120, 4165-4165.	0.6	0
156	Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response. <i>Blood</i> , 2012, 120, 3669-3669.	0.6	0
157	Role of surveillance imaging in the management of peripheral T-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8543-8543.	0.8	0
158	Reduction of Mitochondrial Superoxide By Carbon Nanotube Scaffolds Enhances Ex Vivo Expansion of Human Cord Blood Progenitor Cells. <i>Blood</i> , 2014, 124, 2928-2928.	0.6	0
159	Impact of Post-Remission Consolidation Modalities in the Clinical Outcomes of Acute Myeloid Leukemia Patients in First Remission - Is There a Role for Autologous Hematopoietic Stem Cell Transplant?. <i>Blood</i> , 2015, 126, 3184-3184.	0.6	0
160	Mechanism of Action of Azacytidine in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 4315-4315.	0.6	0
161	Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort. <i>Blood</i> , 2016, 128, 1871-1871.	0.6	0
162	In Vitro Expanded $\beta$ T Cells Derived from Cord Blood Induce Potent and Specific Cytotoxicity Against Human Acute Myeloid Leukemia Cells. <i>Blood</i> , 2016, 128, 2168-2168.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Unmanipulated Haploidentical Transplant Followed By Post-Transplant Cyclophosphamide and Selective Ex Vivo T-Cell Depleted Haploidentical Transplant Results in Comparable Outcome As Unrelated Cord Blood Transplant for Adults with Haematological Malignancies- a Multicenter Study in Singapore. <i>Blood</i> , 2019, 134, 4588-4588.	0.6	0
164	A Biophysically Defined MSC Subpopulation for Enhanced Homing and Immunosuppression. <i>Blood</i> , 2019, 134, 2078-2078.	0.6	0
165	High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore. <i>Blood</i> , 2019, 134, 4509-4509.	0.6	0